60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given New $4.20 Price Target at Ascendiant Capital Markets

60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its target price cut by Ascendiant Capital Markets from $11.20 to $4.20 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts also recently weighed in on the stock. HC Wainwright boosted their target price on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Wall Street Zen upgraded shares of 60 Degrees Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.10.

60 Degrees Pharmaceuticals Stock Down 3.9%

60 Degrees Pharmaceuticals stock opened at $1.74 on Thursday. The company’s 50-day moving average price is $2.67 and its 200-day moving average price is $3.73. 60 Degrees Pharmaceuticals has a twelve month low of $1.29 and a twelve month high of $17.68. The company has a market cap of $4.59 million, a PE ratio of -0.13 and a beta of 3.27.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.